M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 7.68 EUR 4.35% Market Closed
Market Cap: €144m

Operating Margin

-784%
Current
Improving
by 65.4%
vs 3-y average of -849.5%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-784%
=
Operating Income
€-30.7m
/
Revenue
€3.9m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-784%
=
Operating Income
€-30.7m
/
Revenue
€3.9m

Peer Comparison

Country Company Market Cap Operating
Margin
FR
Maat Pharma SA
PAR:MAAT
144m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
391.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
173.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.9B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 95% of companies in France
Percentile
5th
Based on 2 333 companies
5th percentile
-784%
Low
-17 526.7% — 1.3%
Typical Range
1.3% — 11.5%
High
11.5% — 89 700%
Distribution Statistics
France
Min -17 526.7%
30th Percentile 1.3%
Median 6.1%
70th Percentile 11.5%
Max 89 700%

Maat Pharma SA
Glance View

Market Cap
144m EUR
Industry
Biotechnology

Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.

MAAT Intrinsic Value
6.04 EUR
Overvaluation 21%
Intrinsic Value
Price
M
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-784%
=
Operating Income
€-30.7m
/
Revenue
€3.9m
What is Maat Pharma SA's current Operating Margin?

The current Operating Margin for Maat Pharma SA is -784%, which is above its 3-year median of -849.5%.

How has Operating Margin changed over time?

Over the last 3 years, Maat Pharma SA’s Operating Margin has increased from -1 135.9% to -784%. During this period, it reached a low of -1 135.9% on Jun 30, 2022 and a high of -636.3% on Jun 30, 2023.

Back to Top